U.S. markets closed

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1500-0.0500 (-4.17%)
At close: 4:00PM EST
Full screen
Loading interactive chart...
  • InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
    Business Wire

    InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine

    InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled "A study of probable benefit of a bioresorbable polymer scaffold for safety and neurological recovery in patients with complete thoracic spinal cord injury: 6-month results from the INSPIRE study."

  • Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?
    Simply Wall St.

    Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
    Business Wire

    InVivo Therapeutics Announces Closing of $15.0 Million Public Offering

    InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.